On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback